Payment overview · 2025
General Payments
$1,506.32
85 reported records · 13 companies
Healthcare provider profile · identity verified
Cecil Todd Holbert, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PHILIPPI, WV · NPI 1003803891
Verified facts
What the public records show
CMS Open Payments records show Cecil Todd Holbert, M.D. received $1,506.32 in general payments during 2025 across 85 reported records.
ABBVIE INC. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $305.56 | 20.3% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $227.21 | 15.1% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $223.53 | 14.8% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $204.29 | 13.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $109.59 | 7.3% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $93.03 | 6.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $75.64 | 5.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.60 | 4.6% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $55.50 | 3.7% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $43.17 | 2.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.08 | 2.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.21 | 2.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.91 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,506.32 | 85 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $227.21 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $227.21 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $164.05 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $156.36 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $156.36 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $141.64 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $141.64 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.92 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $116.43 | 12 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $93.03 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $88.88 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $75.64 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.92 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $55.50 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $47.93 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $47.93 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $47.93 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $47.49 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $43.17 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.21 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $36.72 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.88 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 146 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 222 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
222 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
146 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 485 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 474 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 375 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 66 |
| Lisinopril | Lisinopril | 315 | 70 |
| Furosemide | Furosemide | 287 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 280 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 277 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 250 | 46 |
| Omeprazole | Omeprazole | 247 | 56 |
| Gabapentin | Gabapentin | 227 | 45 |
| Losartan Potassium | Losartan Potassium | 222 | 47 |
| Ozempic | Semaglutide | 222 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 217 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 212 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 46 |
| Montelukast Sodium | Montelukast Sodium | 198 | 41 |
| Clonazepam | Clonazepam | 192 | 24 |
| Potassium Chloride | Potassium Chloride | 189 | 42 |
| Metformin Hcl Er | Metformin Hcl | 178 | 35 |
| Lorazepam | Lorazepam | 175 | 29 |
| Tramadol Hcl | Tramadol Hcl | 165 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 159 | 16 |
| Trazodone Hcl | Trazodone Hcl | 154 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 42 |
| Eliquis | Apixaban | 146 | 36 |
| Famotidine | Famotidine | 146 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 24 |
| Metformin Hcl | Metformin Hcl | 137 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 136 | 19 |
| Sertraline Hcl | Sertraline Hcl | 135 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 130 | 20 |
| Glimepiride | Glimepiride | 118 | 22 |
| Jardiance | Empagliflozin | 116 | 20 |
| Carvedilol | Carvedilol | 115 | 27 |
| Fluconazole | Fluconazole | 115 | 31 |
| Simvastatin | Simvastatin | 113 | 24 |
| Allopurinol | Allopurinol | 112 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 107 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 22 |
| Alprazolam | Alprazolam | 91 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 91 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 20 |
| Ezetimibe | Ezetimibe | 87 | 20 |
| Meloxicam | Meloxicam | 85 | 19 |
| Diazepam | Diazepam | 82 | 13 |
| Prednisone | Prednisone | 81 | 38 |
| Valsartan | Valsartan | 81 | 14 |
| Nystatin | Nystatin | 76 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 13 |
| Irbesartan | Irbesartan | 73 | 15 |
| Pregabalin | Pregabalin | 72 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 18 |
| Atenolol | Atenolol | 69 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 69 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 14 |
| Cefuroxime | Cefuroxime Axetil | 68 | 47 |
| Alendronate Sodium | Alendronate Sodium | 66 | 12 |
| Trulicity | Dulaglutide | 66 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | 12 |
| Promethazine Hcl | Promethazine Hcl | 65 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 41 |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | suppressed |
| Azithromycin | Azithromycin | 59 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 14 |
| Torsemide | Torsemide | 57 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 57 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | suppressed |
| Sucralfate | Sucralfate | 56 | 13 |
| Lovastatin | Lovastatin | 54 | 12 |
| Mirtazapine | Mirtazapine | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Entresto | Sacubitril/Valsartan | 51 | 12 |
| Ibuprofen | Ibuprofen | 51 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 50 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 50 | 13 |
| Meclizine Hcl | Meclizine Hcl | 48 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 11 |
| Methocarbamol | Methocarbamol | 46 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Aripiprazole | Aripiprazole | 42 | suppressed |
| Cefdinir | Cefdinir | 42 | 33 |
| Nitroglycerin | Nitroglycerin | 42 | 19 |
| Novolog Flexpen | Insulin Aspart | 42 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 25 |
| Dexlansoprazole Dr | Dexlansoprazole | 40 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 11 |
| Spironolactone | Spironolactone | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 34 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 13 |
| Celecoxib | Celecoxib | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Cilostazol | Cilostazol | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 17 |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 25 | suppressed |
| Etodolac | Etodolac | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 17 |
| Nystop | Nystatin | 24 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 16 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Fentanyl | Fentanyl | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Daliresp | Roflumilast | 12 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,506.32 · 85 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, YUPELRI, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error